Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan

References

• Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord.2017;2(3):137–52.
   Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26(10):2159–67.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24(3):387–400.
   PubMed Web of Science ®Google Scholar
• Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–8.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000;43(11):2445–54.
   PubMed Web of Science ®Google Scholar
• Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422–31.
   PubMed Web of Science ®Google Scholar
• Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA. Jr., Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104–9.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019;78(5):648–56.
   PubMed Web of Science ®Google Scholar
• Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford). 2015;54(1):144–51.
   PubMed Web of Science ®Google Scholar
• Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2016;68(2):299–311.
   PubMed Web of Science ®Google Scholar
• Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al.; Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009;60(8):2490–8.
   PubMed Web of Science ®Google Scholar
• Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al.; Scleroderma Clinical Trials Consortium. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2012;64(10):3420–9.
   PubMedGoogle Scholar
• Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, et al.; EUSTAR orators. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):103–9.
   PubMed Web of Science ®Google Scholar
• Maurer B, Graf N, Michel BA, Müller-Ladner U, Czirják L, Denton CP, et al.; EUSTAR co-authors. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74(6):1124–31.
   PubMed Web of Science ®Google Scholar
• Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, et al. Clinical course of Japanese patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol.
   Web of Science ®Google Scholar
• Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis. 2006;65(10):1325–9.
   PubMed Web of Science ®Google Scholar
• Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013;4(2):627–35.
   PubMedGoogle Scholar
• Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, et al.; EUSTAR coauthors. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016;75(10):1743–8.
   PubMed Web of Science ®Google Scholar
• Nagaraja V, Matucci-Cerinic M, Furst DE, Kuwana M, Allanore Y, Denton CP, et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol.
   Web of Science ®Google Scholar
• Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018;77(4):563–70.
   PubMed Web of Science ®Google Scholar
• Yanaba K. Strategy for treatment of fibrosis in systemic sclerosis: present and future. J Dermatol. 2016;43(1):46–55.
   PubMed Web of Science ®Google Scholar
• Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al.; EUSTAR. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010;37(7):1488–501.
   PubMed Web of Science ®Google Scholar
• Ross L, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, et al. The role of inflammatory markers in assessment of disease activity in systemic sclerosis. Clin Exp Rheumatol. 2018;36(Suppl113)(4):126–34.
   Google Scholar
• Kawaguchi Y. Contribution of interleukin-6 to the pathogenesis of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(2_suppl):S6–S12.
   Google Scholar
• Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, et al.; EUSTAR coauthors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–92.
   PubMed Web of Science ®Google Scholar
• White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995;38(3):351–60.
   PubMedGoogle Scholar
• Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–40.
   PubMed Web of Science ®Google Scholar
• Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, et al. Abatacept in early diffuse cutaneous systemic sclerosis: Results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol. 2020;72(1):125–36.
   PubMed Web of Science ®Google Scholar
• Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomized, double-blind, placebo-controlled multicenter trial. Ann Rheum Dis. 2020;79(5):618–25.
   PubMed Web of Science ®Google Scholar